Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo

Nature Medicine

Volumn 2, Issue 5, 1996, Pages 567-573

  Manome, Yoshinobu ^a   Wen, Patrick Y ^b   Dong, Yonghe ^a   Tanaka, Toshihide ^a   Mitchell, Beverly S ^c   Kufe, Donald W ^a   Fine, Howard A ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; DEOXYCYTIDINE KINASE;

ANIMAL CELL; ARTICLE; CANCER THERAPY; GENE THERAPY; GENE TRANSFER; GLIOMA; NONHUMAN; PRIORITY JOURNAL; RAT; VIRUS TRANSMISSION;

ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BRAIN NEOPLASMS; CYTARABINE; DEOXYCYTIDINE KINASE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENETIC VECTORS; GLIOSARCOMA; HUMANS; MALE; PRODRUGS; RATS; RATS, INBRED F344; SARCOMA, EXPERIMENTAL; SURVIVAL ANALYSIS; TRANSFECTION;

EID: 0029924620     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm0596-567     Document Type: Article

References (35)

1. Anderson, W.F. Human gene therapy. Science 256, 808-813 (1992).
2. Mullen, C.A., Kilstrup, M. & Blaese, R.M. Transfer of the bacterial gene for cytosine deaminase to mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc. Natl. Acad. Sci. USA 89, 33-37 (1992).
3. Culver, K.W. et al. In vivo gene transfer with retroviral-vector producer cells for treatment of experimental brain tumors. Science 256, 1550-1552 (1992).
4. Moolten, F.L. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281 (1986).
5. Ellison, R.R. et al. Arabinosyl cytosine: A useful agent in the treatment of acute leukemia in adults. Blood 32, 507-523 (1968).
6. Cadman, E., Farber, L., Berd, D. & Bertino, J. Combination therapy for diffuse histiocytic lymphoma that includes antimetabolites. Cancer Treat. Rep. 61, 1109-1116 (1977).
7. Graham, F.L. & Whitmore, G.F. Studies in mouse L-cells on the incorporation of 1-β-D-arabinofuranosylcytosine into DNA and on inhibition of DNA polymerase by 1-β-D-arabinofuranosylcytosine-5′-triphosphate. Cancer Res. 30, 2636-2644 (1970).
8. Kufe, W.D. et al. Correlation of cytotoxicity with incorporation of ara-C into DNA. J. Biol. Chem. 225, 8997-9000 (1980).
9. Kufe, D., Spriggs, D., Egan, E.M. & Munroe, D. Relationships among Ara-CTP pools, formation of (Ara-C)DNA, and cytotoxicity of human leukemic cells. Blood 64, 54-58 (1984).
10. Early, A.P., Preisler, H.D., Slocum, H. & Rustum., Y.M. A pilot study of high dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: Clinical response and pharmacology. Cancer Res. 42, 1587-1594 (1982).
11. Colly, L.P. & Van Bekkum, D.W. A recommendation for high dose Ara-C treatment based on studies on a slow growing leukemia model (BNML). Med. Pediatr. Oncol. 209 (suppl. 1), 209-220 (1982).
12. Colly, L.P., Peters, W.G. & Willemze, R. Effect of the interval between high dose 1-β-D-arabinofuranosylcytosine injections on leukemic cell load, intestinal toxicity, and normal hematopoietic stem cells in a rat model for acute myelogenous leukemia. Cancer Res. 46, 3825-3827 (1986).
13. Colly, L.P., van Bekkum, D.W. & Hagenbeek, A. Cell kinetic studies after high dose Ara-C and adriamycin treatment in a slowly growing rat leukemia model (BNML) for human acute myelocytic leukemia. Leuk. Res. 8, 945-952 (1984).
14. Vaughan, W.P. & Burke, P.J. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-β-D-arabinofuranosylcytosine in a rat model. Cancer Res. 43, 2005-2009 (1983).
15. Wiley, J.S., Jones, S.P., Sawyer, W.H. & Paterson, A.R.D. Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J. Clin. Invest. 69, 479-189 (1982).
16. Fram, R.J., Egan, E.M. & Kufe, D.W. Accumulation of leukemic cell DNA strand breaks with adriamycin and cytosine arabinoside. Leuk. Res. 7, 243-249 (1983).
17. Kufe, D.W., Munroe, D., Herrick, D., Egan, E. & Spriggs, D. Effects of 1-β-D-arabinofuranosylcytosine incorporation on eukaryotic DNA template function. Mol. Pharmacol. 26, 128-134 (1984).
18. Mikita, T. & Beardsley, G.P. Functional consequences of the arabinosylcytosine structural lesion in DNA. Biochemistry 27, 4698-4705 (1988).
19. Ohno, Y., Spriggs, D., Matsukage, A., Ohno, T. & Kufe, D. Effects of 1-β-D-arabinofuranosylcytosine incorporation on elongation of specific DNA sequences by DNA polymerase β1. Cancer Res. 48, 1494-1498 (1988).
20. Plagemann, P.G.W., Marz, R. & Wohlhueter, R.M. Transport and metabolism of deoxycytidine and 1-β-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation and regulation of triphosphate synthesis. Cancer Res. 38, 978-989 (1978).
21. Engelhardt, J.F. et al. Direct gene transfer of human CFTR into human bronchial epitheria of xenographs with El-deleted adenoviruses. Nature Genet. 4, 27-34 (1993).
22. Engelhardt, J.F., Ye, X., Doranz, B. & Wilson, J.M. Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver Proc. Natl. Acad. Sci. USA 91, 6196-6200 (1994).
23. Tapscott, S.J. et al. Gene therapy of rat 9L gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. USA 91, 8185-8189 (1994).
24. Chottiner, E.G. et al. Cloning and expression of human deoxycytidine kinase cDNA. Proc. Natl. Acad. Sci. USA 88, 1531-1535 (1991).
25. Housey, G.M. et al. Overproduction of protein kinase C causes disordered growth control in rat fibroblast. Cell 52, 343-354 (1988).
26. Chirgwin, J.M., Pryzbyla, A.E., MacDonald, R.J. & Rutter, W.J. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease. Biochemistry 18, 5294-5299 (1979).
27. Manome, Y., Datta, R. & Fine, H.A. Early response gene induction following DNA damage in astrocytoma cell lines. Biochem. Pharmacol. 45, 1677-1684 (1993).
28. Manome, Y., Abe, M., Hagen, M.F., Fine, H.A. & Kufe, D.W. Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer cells to ganciclovir. Cancer Res. 54, 5408-5413 (1994).
29. Freeman, S.M. et al. The "bystander effect": Tumor regression with a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283 (1993).
30. Major, P.P., Egan, E.M., Herrick, D.J. & Kufe, D.W. Effect of ara-C incorporation on deoxyribonucleic acid synthesis in cells. Biochem. Pharmacol. 31, 2937-2940 (1982).
31. Major, P.P., Egan, E.M., Beardsley, G.P., Minden, M.D. & Kufe, D.W. Lethality of human myeloblasts correlates with the incorporation of arabinofuranosylcytosine into DNA. Proc. Natl. Acad. Sci. USA 78, 3235-3239 (1981).
32. Kobayashi, N., Allen, N., Clendenon, N.R. & Ko, L.-W. An improved rat brain-tumor model. J. Neurosurg. 53, 808-815 (1980).
33. Graham, F.L., Smiley, J., Russel, W.C. & Nairn, R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-72 (1977).
34. McGrory, W.J., Bautista, D.S. & Graham, F.L. A simple technique for the rescue of early region 1 mutations into infectious human adenovirus type 5. Virology 163, 614-617 (1988).
35. Graham, F.L. & Prevec, L. Manipulation of adenovirus vectors. in Methods in Molecular Biology (ed. Murray, E.J.) 109-128 (Humana Press Inc., Clifton, New Jersey, 1991).